Home
/ AnGes
/ Competitors

AnGes Competitors and Similar CompaniesClear all

AnGes's competitors and similar companies include Lexicon Pharmaceuticals, Intellia Therapeutics, Mustang Bio and Ionis Pharmaceuticals.

	AnGes AnGes is a biopharmaceutical company specializing in R&D and practical application of genetic medicine.	Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.	Intellia Therapeutics Intellia Therapeutics is a genome editing company that caters to the biotechnology industry.	Mustang Bio Mustang Bio is a clinical-stage biopharmaceutical company that specializes in the development of cell and gene therapies.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Founding Date	Founding Date 1999	Founding Date 1995	Founding Date 2014	Founding Date 2015	Founding Date 1989
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech clinical research healthtech	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma
Locations	Locations Ibaraki, JP HQ Fujisawa, JP Ibaraki, JP Kawasaki, JP Minato City, JP Bethesda, US	Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more	Locations Cambridge, US HQ	Locations Worcester, US HQ	Locations Carlsbad, US HQ Vancouver, CA Stuttgart, DE Dublin, IE Dublin, IE Lisboa, PT London, GB see more
Employees	Employees 5562% decrease	Employees 20216% increase	Employees 40323% decrease	Employees 693% decrease	Employees 1,40231% increase
Valuation ($)	Valuation ($) 78.3 m	Valuation ($) 737.4 m	Valuation ($) 1.7 b	Valuation ($) 11.2 m	Valuation ($) 6.3 b
Financial
Revenue (est.)	Revenue (est.) ¥874.1m (FY, 2025)	Revenue (est.) $49.8m (FY, 2025)	Revenue (est.) $67.7m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $943.7m (FY, 2025)
Cost of goods	Cost of goods ¥499.9m (FY, 2025)	Cost of goods $274k (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods $15.9m (FY, 2025)
Gross profit	Gross profit ¥374.2m (FY, 2025)	Gross profit $49.5m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit $927.8m (FY, 2025)
Net income	Net income (¥5.1b) (FY, 2025)	Net income ($50.3m) (FY, 2025)	Net income ($412.7m) (FY, 2025)	Net income ($1.9m) (FY, 2025)	Net income ($381.4m) (FY, 2025)
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 1 (FY, 2016)	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 1 (FY, 2023)
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 2 (FY, 2016)	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 17 (FY, 2024)